Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia

JAMA Psychiatry

Volumn 72, Issue 1, 2015, Pages 5-13

  Sarpal, Deepak K ^a   Robinson, Delbert G ^a,c   Lencz, Todd ^a,b,c   Argyelan, Miklos ^a   Ikuta, Toshikazu ^d   Karlsgodt, Katherine ^a,b   Gallego, Juan A ^a,b,c   Kane, John M ^a,b,c   Szeszko, Philip R ^a,b,c   Malhotra, Anil K ^a,b,c  

^a Department of Psychiatry Zucker Hillside Hospital North Shore LIJ Health System ^*  (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; ANTERIOR CINGULATE; ANTERIOR INSULA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CONNECTOME; CONTROLLED STUDY; CORPUS STRIATUM; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PREFRONTAL CORTEX; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT RESPONSE; BRAIN CORTEX; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PROCEDURES; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BRIEF PSYCHIATRIC RATING SCALE; CEREBRAL CORTEX; CONNECTOME; CORPUS STRIATUM; DRUG MONITORING; EPISODE OF CARE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEURAL PATHWAYS; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84920848264     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.1734     Document Type: Article

References (42)

1. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44(7):660-669.
2. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474-1486.
3. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776-786.
4. Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry. 2008; 63(1):114-117.
5. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry. 2010;67(7):683-691.
6. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 1992;160:179-186.
7. Nielsen MØ, Rostrup E, Wulff S, et al. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry. 2012;71(10): 898-905.
8. Koch K, Wagner G, Nenadic I, et al. Fronto-striatal hypoactivation during correct information retrieval in patients with schizophrenia: an fMRI study. Neuroscience. 2008;153(1):54-62.
9. Quidé Y, Morris RW, Shepherd AM, Rowland JE, Green MJ. Task-related fronto-striatal functional connectivity during working memory performance in schizophrenia. Schizophr Res. 2013;150(2-3):468-475.
10. Tu PC, Lee YC, Chen YS, Li CT, Su TP. Schizophrenia and the brain's control network: aberrant within- and between-network connectivity of the frontoparietal network in schizophrenia. Schizophr Res. 2013;147(2-3):339-347.
11. Orliac F, Naveau M, Joliot M, et al. Links among resting-state default-mode network, salience network, and symptomatology in schizophrenia. Schizophr Res. 2013;148(1-3):74-80.
12. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5(3):267-271.
13. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry. 2011;16(1): 67-75.
14. Dandash O, Fornito A, Lee J, et al. Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis. Schizophr Bull. 2014;40(4):904-913
15. Fornito A, Harrison BJ, Goodby E, et al. Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis. JAMA Psychiatry. 2013;70(11):1143-1151.
16. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994;11 (4):245-256.
17. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081-1090.
18. Lui S, Li T, Deng W, et al. Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. Arch Gen Psychiatry. 2010;67(8):783-792.
19. Bolding MS, White DM, Hadley JA, Weiler M, Holcomb HH, Lahti AC. Antipsychotic drugs alter functional connectivity between the medial frontal cortex, hippocampus, and nucleus accumbens as measured by H215O PET. Front Psychiatry. 2012;3:105.
20. Sambataro F, Blasi G, Fazio L, et al. Treatment with olanzapine is associated with modulation of the default mode network in patients with schizophrenia. Neuropsychopharmacology. 2010;35 (4):904-912.
21. Nielsen MO, Rostrup E, Wulff S, et al. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry. 2012;69(12):1195-1204.
22. Di Martino A, Scheres A, Margulies DS, et al. Functional connectivity of human striatum: a resting state FMRI study. Cereb Cortex. 2008;18 (12):2735-2747.
23. Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. J Oper Psychiatr. 1980;11:48-65.
24. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15(4):870-878.
25. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-381.
26. Postuma RB, Dagher A. Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb Cortex. 2006;16(10):1508-1521.
27. Polli FE, Barton JJ, Thakkar KN, et al. Reduced error-related activation in two anterior cingulate circuits is related to impaired performance in schizophrenia. Brain. 2008;131(pt 4):971-986.
28. Lahti AC, Holcomb HH, Weiler MA, et al. Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology. 2004;29(1):171-178.
29. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23.
30. Jensen J, Willeit M, Zipursky RB, et al. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology. 2008;33(3):473-479.
31. Bhattacharyya S, Crippa JA, Allen P, et al. Induction of psychosis by Ä9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry. 2012;69(1):27-36.
32. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006;29(2):409-416.
33. Menon M, Schmitz TW, Anderson AK, et al. Exploring the neural correlates of delusions of reference. Biol Psychiatry. 2011;70(12):1127-1133.
34. Sorg C, Manoliu A, Neufang S, et al. Increased intrinsic brain activity in the striatum reflects symptom dimensions in schizophrenia. Schizophr Bull. 2013;39(2):387-395.
35. Nejad AB, Ebdrup BH, Glenthøj BY, Siebner HR. Brain connectivity studies in schizophrenia: unraveling the effects of antipsychotics. Curr Neuropharmacol. 2012;10(3):219-230.
36. Abbott CC, Jaramillo A, Wilcox CE, Hamilton DA. Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations. Curr Med Chem. 2013;20(3): 428-437.
37. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL. Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology. 2009; 34(13):2675-2690.
38. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006;163(3):529-531.
39. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: ameta-analysis. Am J Psychiatry. 2010;167(7):763-772.
40. Bertolino A, Fazio L, Caforio G, et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain. 2009;132(Pt 2):417-425.
41. Konova AB, Moeller SJ, Tomasi D, Volkow ND, Goldstein RZ. Effects ofmethylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. JAMA Psychiatry. 2013;70(8):857-868.
42. Schmidt A, Smieskova R, Aston J, et al. Brain connectivity abnormalities predating the onset of psychosis: correlation with the effect of medication. JAMA Psychiatry. 2013;70(9):903-912.